07:00 , Oct 8, 2015 |  BC Innovations  |  Product R&D

Medicines Co.'s double play

While inhibiting β-lactamases is one of the dominant strategies for combating antibiotic resistance, companies have only had success targeting one of the two classes of the enzyme, serine β-lactamases, and have made little progress against...